XPO1 and breast carcinoma: In summary, targeting key molecules related to Cyt c function in these pathways (such as CRM1, tRNA binding sites, IL-6 receptors) may provide a new strategy for breast cancer treatment by restoring the pro-apoptotic activity of Cyt c.